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abstract
introduction. Factors promoting nerve cell ingrowth are considered responsible for chronic back pain resulting 
from the intervertebral disc degeneration (IDD). One of the recent exploratory IDD treatments is stem cell 
transplantation therapy. The CD271 (low-affinity nerve growth factor receptor) has been identified as a mark-
er of the most homogeneous mesenchymal stem cell (MSC) subset. It is capable of promoting differentiation 
along adipogenic, osteogenic and chondrogenic lineages and producing significantly higher levels of cytokines 
as compared to the total population of plastic adherence-mesenchymal stem cells (PA-MSCs). 
We investigated the ability of CD271+ MSCs to differentiate into chondrocyte-like cells of the nucleus pulposus 
(NP) of intervertebral disc. We also examined CD271– MSCs, using PA-MSCs as a control cell population. 
Material and methods. Bone marrow derived PA-MSCs and its two subsets, CD271– MSCs and CD271+ MSCs, 
were seeded in collagen scaffolds. After two weeks of growth in NP-differentiation medium, RNA was isolated 
from cells-scaffold constructs and was analyzed by q-PCR for expression of NP markers. Glycosaminoglycans 
were analyzed biochemically directly in cells-scaffold constructs.
results. Expression of NP markers — extracellular matrix components such as aggrecan, collagen type II and 
glycosaminoglycans on both RNA and the protein levels — was significantly higher in CD271– MSCs compared 
to the CD271+ MSCs and PA-MSCs cell populations. 
Conclusions. CD271– MSCs may be superior candidates for NP restorative treatment compared to CD271+ MSCs 
and PA-MSCs due to their ability of expressing NP-supporting extracellular matrix components at levels higher 
than the other two studied MSC subsets. (Folia Histochemica et Cytobiologica 2017, Vol. 55, No. 3, 114–123)
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introduction
The exact mechanisms of the intervertebral disc 
degeneration remain unclear. Pathological changes 
observed during the disc degeneration process have 
both genetic and environmental background and 
are often related to the spine mechanics combined 
with traumatic injury. Following intervertebral disc 
(IVD) degeneration, the biomechanical status of the 
vertebral column is altered, thereby increasing the 
probability of the facet joint degeneration, spondy-
losis, spondylolisthesis, and spinal stenosis. These 
pathologic processes are the main reason for an acute 
or chronic low back or neck pain. Discopathy is also 
responsible for the substantial biochemical changes in 
the disc structure. The necessity to better understand 
the pathological phenomena behind biochemistry 
and cell biology of intervertebral discs spurred the 
research on stem cells and the regenerative stem cell 
transplantation as a new potentially curative treat-
ment for IVD [1–3]. 
To date, mesenchymal stem cells (MSCs) are most 
frequently used in cell-based therapies due to the 
ease of their availability and suitability in autologous 
transplantations. The best-fit definition of mesenchy-
mal stem cells points to their multipotent, stromal 
phenotype with the ability to differentiate into cells 
of mesenchymal origin such as bone, cartilage and 
adipocytes. MSCs show a high capacity to adhere to 
plastic surfaces [4] and are typically defined by the 
expression of CD73, CD90, CD105, and lack of ex-
pression of hematopoietic markers and MHC class II 
antigens [5]. However, MSCs constitute a very het-
erogeneous population of multipotent progenitor 
cells with a varying proliferative, differentiation and 
immunosuppressive potential that differ in the sets 
of surface markers. These variations relate both to 
the different MSC sources such as bone marrow, 
adipose tissue and Wharton jelly, and to the poten-
tial for differentiation. For instance, in some studies 
the differentiation along adipogenic, osteogenic and 
chondrogenic lineages was observed in only about 
one-third of bone marrow-derived MSC (BM-MSC) 
clones, while most clones (60–80%) displayed only 
osteo- or chondrogenic potential [6]. Other studies 
have demonstrated this trilineage differentiation 
ability for only about 50% of colony-forming cells [7]. 
On the other hand, only about 7% of BM-MSCs were 
able to differentiate toward multiple lineages, when 
their phenotype was tested at a single-cell level [8]. 
Interestingly, tri-, bi-, and uni-directional clones were 
obtained from 100 single-cell derived clones, confirm-
ing that MSCs are composed of cells with different 
differentiation potential [9]. Mareddy and coworkers 
demonstrated the presence of fast- and slow-growing 
MSC clones, where the fast-growing clones were 
tripotent, and slow-growing clones displayed limited 
differentiation ability and often showed morphologi-
cal features associated with cellular senescence [10]. 
Efforts aimed at generation of bio-materials for 
the regenerative stem cell-based therapies focus on 
the search for markers or combination of markers 
allowing isolation of cell populations optimized for 
their subsequent use in transplantation. 
According to several recent reports [11–13], 
expression of CD271 is associated with the most 
homogeneous MSC subset capable of differentiat-
ing along adipogenic, osteogenic and chondrogenic 
lineages, and of producing significantly higher levels 
of cytokines than plastic adherence-mesenchymal 
stromal cells (PA-MSCs) [14–17]. CD271 was initially 
described as a nerve growth factor receptor (NGFR); 
it is also known as LNGFR (low-affinity nerve growth 
factor receptor), and belongs to the low-affinity neu-
rotrophin receptor family and to the tumor necrosis 
factor receptor superfamily [18, 19]. CD271 interacts 
with neurotrophins such as brain-derived neutrophic 
factor (BDNF), neurotrophin-3 and neurotrophin-4, 
and with pro-neurotrophins (proNTs), including 
proNGF and proBDNF [18–20]. This antigen is 
expressed by several cell types, including neurons, 
Schwann cells, mesenchymal stem cells, follicular 
dendritic cells, and melanocytes among other cell 
types [19, 22, 23]. While present on cells of the nerv-
ous system, CD271 is thought to be involved in the 
development, survival, and differentiation of neural 
cells [19–22]. CD271+ MSCs demonstrated also high-
er cell proliferation capacity compared to the entire 
PA-MSC population [23]. However, CD271 has been 
also identified as a marker of tumor initiating cells 
that may affect cell survival and proliferation [24–26]. 
The finding that the CD271+ MSCs can effectively 
differentiate towards cartilage tissue [15, 27, 28] has 
inspired us to investigate the ability of these cells to 
differentiate into chondrocyte-like cells of the nucleus 
pulposus (NP) of IVD. We have also investigated 
CD271– MSCs and compared these cells to the entire 
population of MSCs generated by plastic adherence 
[29–31]. Based on the gene and the glycosamino-
glycans (GAG) expression profiles characteristic 
for healthy NP, we hypothesized that the CD271– 
MSCs may be valuable candidates for NP restorative 
treatment. To the best of our knowledge, this is the 
first study in which chondrocyte-like phenotypes of 
both CD271+ MSCs and CD271– MSCs have been 
compared. 
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Material and methods
Processing of bone marrow and cultures of MSCs. All pa-
tients gave an informed written consent and research was 
carried out in compliance with the Helsinki Declaration. 
The experimental design was approved by the Ethic Com-
mittee of the University of Warmia and Mazury, Olsztyn, 
Poland. Bone marrow aspirates were obtained from patients 
undergoing iliac bone graft or total hip replacement (n = 5, 
2 females, 3 males; median age 53 years, range: 40–70 years) 
using heparin-rinsed trocar and syringe; none of the subjects 
had underlying diseases. 
In addition to the population of plastic adherence-mes-
enchymal stem cells (PA-MSCs) [4], CD271-positive and 
CD271-negative cell subsets were selected. The CD271+ 
subset of MSCs were isolated using immunomagnetic meth-
od based on MACSelect CD271 (LNGFR) Microbeads kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany) according 
to manufacturer’s recommendations and described as 
CD271+ MSCs. Cells remaining after this isolation step were 
considered as CD271 negative and referred to as CD271– 
MSCs. Briefly, a phosphate-buffered saline (PBS)-diluted 
cell fraction of bone marrow was layered over a Ficoll density 
gradient (1.077 g/mL, GE Healthcare, Little Chalfont, UK), 
followed by centrifugation at 400 g at room temperature for 
40 min. Nucleated cells were collected, diluted with two 
volumes of PBS, centrifuged twice at 100 g for 10 min, and 
finally resuspended in DMEM/F-12, GlutaMAX(TM) with 
glucose (3151 mg/L) (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA), supplemented with 10% fetal bovine 
serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA) and 
1% 10,000-U penicillin/streptomycin (P/S) (Sigma-Aldrich, 
St. Louis, MO, USA) and incubated at 37°C in a 5% CO2 
atmosphere in a T-75 flask (Becton Dickinson, New Jersey, 
NJ, USA). After 5 days, the medium was replaced and un-
attached cells were removed. Thereafter, the medium was 
replenished every 2–3 days, and, after reaching confluency 
at about 14 days in culture, the cells were digested with 
0.05% trypsin/ethylenediaminetetra acetic acid (EDTA) 
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) 
for microencapsulation. In the first step of cell isolation 
using a Ficoll density gradient, usually about 1 × 108 of 
mononuclear cells were obtained, and in the next step in 
which immunomagnetic method was applied, about 2% cells 
positive for CD271 marker were obtained and the remaining 
98% were CD271– cells. This yield of CD271+ cells was con-
sistent throughout all cell purification experiments (n = 5). 
immunocytochemical characterization of the analyzed 
cell populations. The phenotype of MSCs was confirmed 
immunocytochemically [32] using commonly recognized 
positive (CD90, CD73) as well as negative (CD45, CD34) 
surface markers of stemness.
Samples in 24-well culture plate were rinsed briefly in 
0.1 M PBS and fixed with 4% buffered paraformaldehyde 
(pH 7.4) for 10 min. Next, MSCs were permeabilized with 
0.025% Triton X-100 (Sigma-Aldrich) for 5 min. After this 
step, those cells were incubated with a blocking mixture 
containing 10% normal goat serum (Invitrogen) in PBS for 
30 min at 37°C to reduce non-specific background staining. In 
the next step, the MSCs were washed with PBS (3 × 5 min). 
After a wash, those cells were incubated with a mixture of 
primary antibodies for CD90 (mouse anti-human, Becton 
Dickinson), CD73 (mouse anti-human, Invitrogen), CD45 
(mouse anti-human, Becton Dickinson) and CD34 (mouse 
anti-human, Invitrogen) overnight in the humid chamber at 
4°C. Next, MSCs were washed again with PBS (3 × 5 min) 
and primary antisera were then visualized by a mixture of 
secondary antibodies (Alexa Fluor 488 and Alexa Fluor 
555; Jackson Immuno Research Labs, Baltimore Pike, PA, 
USA) for 1 h at room temperature and in the darkness. The 
working concentration of primary and secondary antibodies 
was 1:500. After the incubation, those cells were washed 
again with PBS (3 × 5 min) and then were mounted with 
mounting medium with DAPI (Santa Cruz Biotechnology, 
Dallas, Texas, USA).
Microencapsulation and 3d cultures of mesenchymal stem 
cell subsets. Rat-tail collagen type I (Becton Dickinson, 
New Jersey, NJ, USA) was first neutralized by 1 N sodium 
hydroxide and diluted into a final concentration of 2 mg/mL. 
CD271+ MSCs, CD271– MSCs, and PA-MSCs were sus-
pended in the neutralized collagen solution to make up cell 
matrix mixtures with initial cell density of 1,000 cells in 5 µL 
droplets. Liquid droplets were then dispensed onto a non-ad-
hesive surface of sterile parafilm sheets placed in Petri dishes 
and incubated at 37°C in a 5% CO2 atmosphere for 45 min 
to induce gelation of collagen [33]. The gelated micro-
spheres were then suspended in a chemically defined basal 
medium containing DMEM supplemented with 10 ng/mL 
transforming growth factor 1 (TGF-1; R & D Systems, Min-
neapolis, MN, USA), 100 nmol/L dexamethasone, 50 g/mL 
ascorbate 2-phosphate, 100 g/mL sodium pyruvate, 40 g/mL 
proline and ITS-plus (Sigma-Aldrich), and cultured at 2% 
oxygen using O2/CO2 incubator (Sanyo Moriguchi, Osaka, 
Japan) for 10 days [34]. 
Measurement of glycosaminoglycans content. To determine 
the GAG content in the microspheres, a modified 1,9-di-
methylmethylene blue (DMMB) dye-binding assay was used 
[35]. For each population, 30 microspheres were placed in 
a phosphate buffer at pH 6.5 (50 mM phosphate buffer, 
5 mM EDTA, and 5 mM L-cysteine) containing 5 µL of 
20 mg/mL proteinase K (Sigma-Aldrich) at 60°C overnight to 
solubilize the proteoglycans. Unlike the traditional DMMB 
assay, 10% propan-l-ol was included in the decomplexation 
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solution to enhance DMMB signal at 656 nm. Absorbance 
was measured using a microplate reader (Infinite 200 PRO, 
TECAN, Männedorf, Switzerland). To evaluate the amount 
of GAGs in the samples, calibration curve was constructed 
using chondroitin 6-sulfate (Sigma-Aldrich) as a standard, 
and the GAG concentration was determined using its linear 
region between 0.0625 and 2 mg/100 mL. Filtration of the 
pre-heated, proteinase K-treated samples eliminated most 
of the interfering DNA, resulting in the total loss of DNA-
-DMMB complexes. To avoid possible overestimate of the 
GAG concentration due to the traces of the DNA-DMMB 
complexes, all samples of microspheres were filtered fol-
lowing proteinase K treatment. 
Measurement of the expression of nP cellular markers by 
qPCr. Microspheres were homogenized with 1 mL of TRI 
reagent (Sigma-Aldrich), 100 mL of 1-bromo-3-chloro-
propane (Sigma-Aldrich) were added to the homogenates 
and the mixture was shaken vigorously for 15 min. The 
mixture was phase-separated following centrifugation at 
12,000 g for 15 min at 4°C, where RNA remained in the 
upper aqueous phase while DNA and proteins separated 
into the interphase and organic phase. RNA was precip-
itated by adding 500 mL of isopropanol and pelleted by 
centrifugation at 12,000 g for 10 min at 4°C. The supernatant 
was removed and RNA pellet was centrifuged at 8000 g for 
5 min at 4°C after washing with 1 mL of 75% diethylpyrocar-
bonate (DEPC)-(Sigma-Aldrich)-treated ethanol. Ethanol 
was removed and RNA pellets were air-dried for 10–15 min, 
dissolved in DEPC-treated water and incubated for 
15 min at 60°C. Reverse transcription of total RNA to 
cDNA was performed using the Thermo Scientific Maxima 
First Strand cDNA Synthesis Kit for RT-qPCR (Thermo 
Fisher Scientific), containing oligo(dT)18 and random hex-
amer primers to prime synthesis of first strand of cDNA. 
The concentration of RNA was 100 ng/µL. The RT-PCR 
conditions were: incubation for 10 min at 25°C followed by 
15 min at 50°C, termination the reaction by heating at 85°C 
for 5 min. To determine the direction of PA-MSCs and their 
subsets differentiation the expression levels of genes char-
acteristic for healthy intervertebral disc, including paired 
box 1 (PAX1), SOX-9, and intercellular matrix proteins: 
aggrecan (ACAN), collagen type I (COLI), collagen type II 
(COLII), and keratin 19 (KRT19) were evaluated (Table 1). 
Real Time PCR was performed using Power SYBR Green 
PCR Master Mix (Roche, Mannheim, Germany) under stan-
dard thermal conditions (LightCycler® 480 Instrument II; 
Roche). The PCR reaction included 100 ng of cDNA, 
10 × concentrated PCR primers, 10 µL of Master Mix, 
and RNase free water in a final volume of 20 µL. The final 
concentration of primers was 1 mM. The qPCR conditions 
were: pre-incubation at 95°C for 5 min followed by 45 
rounds of denaturation at 95°C for 10 s, annealing at 58°C 
for 20 s, extension at 72°C for 30 s, followed by dissocia-
tion curve analysis. The NormFinder software (MOMA, 
Aarhus, Denmark) was used to obtain a set of candidate 
normalization genes according to their expression stability 
in a given sample set and given experimental design. The 
expression levels of genes of interest were normalized to 
the housekeeping 18S ribosomal RNA gene (RNA18S1), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
and b-actin (ACTB) expression using the ∆∆Ct method to 
calculate the relative mRNA levels of each target gene for 
the entire MSCs population. 
Statistical analysis. All results are expressed as mean ± 
standard error. The significance of differences among the 
means of data for gene expression and the GAG quantity 
were analyzed using one-way analysis of variance and the 
Tukey test as a post hoc test. A p-value of less than 0.05 was 
considered statistically significant. 
results
Isolation, microencapsulation and 3D cultures  
of MSCs and its sub-populations for in vitro studies 
In all three investigated cell populations, MSC phe-
notype was confirmed by immunocytochemistry. 
table 1. Primers used for RT-PCR analysis
gene (abbr.) forward primer (5’-3’) reverse primer (5’-3’)
Collagen type II (COL2A1) gaatccagggtcctcaag accagtgaagccacg
Collagen type I (COL1A1) ccagcaaatgttcctttttg aaaattcacaagtccccatc
Aggrecan (ACAN) cagaccgtcagataccc ataggtcctgacccctg
Keratin 19 (KRT19) acaacaatttgtctgcctc atttttattggcaggtcagg
Transcription factor (SOX9) aaatcaacgagaaactggac atttagcacactgatcacac
Paired box 1 (PAX1) attaaatacactcagtcggc atgcacagctacgcc
GAPDH ctctgatttggtcgtattgg gtaaaccatgtagttgaggtc
b-actin (ACTB) gacgacatgagaaaatctg atgatctgggtcatcttctc
RN18S1 atcggggattgcaattattc ctcactaaaccatccaatcg
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The cells were immunopositive for CD90 and CD73 
markers, and immunonegative for CD34 and CD45 
markers (Fig. 1). Following cell count, cells were 
microencapsulated in collagen microspheres after 
reaching the plateau phase in about 2 weeks of cul-
turing as monolayers. MSC microspheres contained 
5 × 105 cells of each subset. 
Glucosaminoglycans content in cell microspheres 
To evaluate the differentiation process of MSCs, 
GAGs’ content produced by cells in the micro-
spheres was measured and expressed in µg/105 
cells. Both MSC subsets showed higher GAG 
biosynthesis activity (1.97 µg/105 cells  and 
3.38 µg/105 cells for CD271+ MSCs and CD271– 
MSCs, respectively) than the control PA-MSCs 
(0.73 µg/105 cells).
New GAG matrix was produced by both MSC 
subsets as shown by the increased GAG content; how-
ever, the significant difference was observed between 
CD271– MSCs and PA-MSCs (Fig. 2). 
Expression of NP gene markers by qPCR
The concentration and quality of the total RNA 
were estimated by measuring the absorbance 
figure 1. Expression of cell surface markers in the analyzed mesenchymal stem cells subsets. Presence of CD73 and CD90 
proteins (red) and absence of CD45 and CD34 expression, Hoechst nuclear stain (blue). Scale bar: 10 µm.
figure 2. GAG content in the analyzed subsets of MSC eval-
uated by 1,9-dimethylmethylene blue (DMMB) dye-binding 
assay. *Statistically significant difference, p < 0.05.
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ratio of 260/280 nm and range 40–200 ng/µL and 
1.80–1.99, respectively. To follow MSC differenti-
ation process the expression of the nucleus pulpo-
sus gene markers was analyzed using quantitative 
PCR. Gene expression analysis of matrix proteins 
regarded as phenotypic markers of nucleus pulpo-
sus chondrocyte-like cells, showed markedly higher 
expression in CD271– MSC of the all studied mark-
ers, with the exception of collagen type I (Fig. 3C). 
Expression of keratin 19 and collagen type II genes 
was significantly higher in CD271– MSCs compared 
to CD271+ MSCs and PA-MSCs, 3 fold and 30 fold, 
respectively. The aggrecan gene expression was signifi-
cantly higher (4-fold) in CD271– MSCs than in CD271+ 
MSCs (Fig. 3A–C). Collagen type I mRNA levels were 
similar in all the studied cell populations (Fig. 3D).
figure 3. Gene expression in the analyzed subsets of MSC evaluated by real-time PCR. a. Aggrecan (ACAN); B. Keratin 19 
(KRT19); C. Collagen type I (COL1A1); d. Collagen type II (COL2A19); E. PAX1; f. SOX9. *, ***Statistically significant 
differences, p < 0.05 and p < 0.001, respectively.
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We measured gene expression of transcription fac-
tors characteristic for normal intervertebral disc [36] 
and found that both PAX1 and SOX9 showed high-
er expression in CD271– MSCs, as compared to the 
CD271– MSCs and PA-MSCs, nearly 30-fold and 
2-fold, respectively (Fig. 3E, F).
discussion
The CD271 antigen has been identified as a marker 
of the most homogeneous mesenchymal stem cell 
(MSC) subset [36]. To date, CD271 molecule has been 
described as one of the most specific markers for the 
isolation of bone marrow BM-MSCs. It is now well 
documented that the proliferation and differentiation 
potential of CD271+ bone marrow-derived MSCs is 
higher than that of the unfractionated source mixture 
of the bone marrow-derived MSCs [36]. Since the 
CD271 antigen is able to promote cell proliferation 
and differentiation along three mesenchymal line-
ages, i.e. adipogenic, osteogenic and chondrogenic 
[27, 28, 38–40], it has been intensely investigated 
as an antigen driving generation of differentiated 
cells suitable for specific therapeutic applications. 
Obtaining the chondrocyte-like phenotype in an at-
tempt to regenerate cartilage has been one of these 
experimental directions. Because it was found that the 
CD271+ MSCs can effectively differentiate towards 
cartilage tissue [15, 27, 28], we decided to check if 
these cells can differentiate into chondrocyte-like 
cells of the nucleus pulposus (NP) of IVD. However, 
since CD271 is a very efficient nerve growth factor 
receptor, its presence may lead to nerve ingrowth 
into NP. Therefore, we also examined phenotype of 
CD271– MSCs and used PA-MSCs as a control cell 
population for the both isolated CD271 cell subsets. 
Although the phenotype of NP cells is closely associ-
ated with that of chondrocytes, still clear differences 
exist [41]. Similarly to the in vitro differentiation of 
MSCs into chondrocytes, their differentiation toward 
an NP-cell phenotype depends on diverse and specific 
parameters such as an appropriate choice of growth 
factors, 3D-matrix, intercellular contacts or environ-
mental conditions mimicking the physiological status 
of IVD such as hypoxia [34].
It is generally accepted to use phenotypic markers 
such as aggrecan and collagen type II, characteristic 
of articular cartilage, to define the nucleus pulposus 
cells phenotype [42–44]. 
Genes encoding molecules characteristic for the 
NP may be valuable for monitoring expression chang-
es during differentiation of MSC subsets toward chon-
drocyte-like cells of nucleus pulposus. With respect to 
the typical chondrogenic markers, aggrecan, collagen 
type II, keratin 19, Sox9, PAX1 and glycosaminogly-
cans, the use of different populations of MSCs in our 
study demonstrated clear differences in chondrogenic 
gene up-regulation and accumulation of GAGs. 
A healthy intervertebral disc is highly hydrated, 
the water content being a key parameter responsible 
for the biophysical properties of the NP [45]. Abun-
dance and unique molecular features of GAGs and 
aggrecan provide IVD with its osmotic properties and 
ability to withstand compressive loads, whereas their 
degradation results first in the impairment of disc 
function and then the onset of its degeneration [46]. 
IVD degeneration is associated with changes in disc 
morphology and composition of extracellular matrix, 
which lead to the loss of correct shape and water 
content. Therefore, to achieve optimal disk recovery, 
an increase in the synthesis of the water-absorbent 
particles needed to restore the cushioning actions is 
needed [47]. We have indeed observed a significant 
increase in the GAG biosynthesis and in aggrecan 
expression in the CD271– MSCs, but not in CD271+ 
MSC and not in PA-MSC populations (Fig. 2, 3A). 
The results obtained by others for these two macro-
molecules differ between reports and largely depend 
on the BM-MSC growth conditions [30, 48]. 
SOX9, responsible for the induction of type II 
collagen expression later during chondrogenic dif-
ferentiation, is the most widely used marker in the 
evaluation of MSC differentiation to chondrocyte-like 
cells [49]. We have found that CD271– MSCs showed 
a significant increase in collagen II and SOX9 expres-
sion compared to the CD271+ MSCs and PA-MSCs. 
Others have shown an increase in type I collagen and 
a reduction in type II collagen present in the degen-
erating NP [50]. There was no difference in the COL 
I expression between any of the experimental groups 
(Fig. 3C). Keratin 19 is another important marker of 
healthy discs, also known as a NP marker in rat and 
human [42, 51, 52]. Keratin 19 is frequently described 
as a notochordal cell marker [51], expression of which 
is induced by the low oxygen tension [53]. Parallel to 
the results obtained for other NP markers, we observed 
a significant increase in the expression of keratin 19 
in the CD271– MSCs subset (Fig. 3B). Others have 
reported significant keratin 19 expression in BM-MSC 
[33]; however, because of multiple cell types present 
in BM-MSC and different culture conditions used, it 
is impossible to discuss the expression of any markers. 
Additionally, there may be yet unknown interactions 
between various cellular BM-MSC components, that 
may influence each other and cross-regulate biology 
of subsets co-existing in one MSC source. 
Nerve growth factor (NGF) is a key neurotrophic 
factor that promotes ingrowth and survival of nerves 
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[54, 55]. Degeneration-initiated changes associated 
with rearrangements of innervation, are linked to the 
increase of nerve ingrowth in the NP, which leads to 
the chronic back pain [56]. Absence of CD271, a NGF 
receptor, should therefore be a favorable feature of 
cell-based NP-regenerative therapy.
Here we have demonstrated, for the first time, 
a great capacity of isolated CD271– MSCs to pro-
duce extracellular matrix components necessary for 
supporting function of healthy IVD. We have shown 
that: (i) CD271– MSCs present a higher differentiation 
potential toward chondrocyte-like cells of nucleus pul-
posus when compared to CD271+ MSCs; and (ii) the 
absence of CD271 in a subset of MSCs likely triggers 
a significantly higher differentiative potential toward 
nucleus pulposus in these cells than in CD271+ MSCs. 
Overall, presented results show that CD271– MSCs 
may be superior candidates for NP restorative treat-
ment compared to CD271+ MSCs and PA-MSCs. 
acknowledgements
This work was sponsored by National Science Center 
(NCN) grants number 2012/07/B/NZ4/01427 and 
2012/05/D/NZ3/02028. 
references
1. An HS, Anderson PA, Haughton VM, et al. Introduction: disc 
degeneration: summary. Spine (Phila Pa 1976). 2004; 29(23): 
2677–2678, indexed in Pubmed: 15564916.
2. Adams M, Roughley P. What is intervertebral disc degenera-
tion, and what causes it? Spine. 2006; 31(18): 2151–2161, doi: 
10.1097/01.brs.0000231761.73859.2c.
3. Hadjipavlou AG, Tzermiadianos MN, Bogduk N, et al. 
The pathophysiology of disc degeneration: a critical re-
view. J Bone Joint Surg Br. 2008; 90(10): 1261–1270, doi: 
10.1302/0301-620X.90B10.20910, indexed in Pubmed: 
18827232.
4. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The de-
velopment of fibroblast colonies in monolayer cultures of 
guinea-pig bone marrow and spleen cells. Cell Proliferation. 
1970; 3(4): 393–403, doi: 10.1111/j.1365-2184.1970.tb00347.x.
5. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage po-
tential of adult human mesenchymal stem cells. Science. 1999; 
284(5411): 143–147, indexed in Pubmed: 10102814.
6. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal 
progenitors from human bone marrow differentiate in vitro 
according to a hierarchical model. J Cell Sci. 2000; 113 (Pt 7): 
1161–1166, indexed in Pubmed: 10704367.
7. Russell KC, Phinney DG, Lacey MR, et al. In vitro high-ca-
pacity assay to quantify the clonal heterogeneity in trilineage 
potential of mesenchymal stem cells reveals a complex hierar-
chy of lineage commitment. Stem Cells. 2010; 28(4): 788–798, 
doi: 10.1002/stem.312, indexed in Pubmed: 20127798.
8. Lee CC, Christensen JE, Yoder MC, et al. Clonal analysis 
and hierarchy of human bone marrow mesenchymal stem 
and progenitor cells. Exp Hematol. 2010; 38(1): 46–54, doi: 
10.1016/j.exphem.2009.11.001, indexed in Pubmed: 19900502.
9. Okamoto T, Aoyama T, Nakayama T, et al. Clonal hetero-
geneity in differentiation potential of immortalized human 
mesenchymal stem cells. Biochem Biophys Res Commun. 
2002; 295(2): 354–361, doi: 10.1016/s0006-291x(02)00661-7.
10. Mareddy S, Crawford R, Brooke G, et al. Clonal isolation 
and characterization of bone marrow stromal cells from pa-
tients with osteoarthritis. Tissue Eng. 2007; 13(4): 819–829, 
doi: 10.1089/ten.2006.0180, indexed in Pubmed: 17371154.
11. Quirici N, Soligo D, Bossolasco P, et al. Isolation of bone 
marrow mesenchymal stem cells by anti-nerve growth factor 
receptor antibodies. Exp Hematol. 2002; 30(7): 783–791, doi: 
10.1016/s0301-472x(02)00812-3.
12. Mabuchi Yo, Houlihan DD, Akazawa C, et al. Prospective 
isolation of murine and human bone marrow mesenchymal 
stem cells based on surface markers. Stem Cells Int. 2013; 
2013: 507301, doi: 10.1155/2013/507301, indexed in Pubmed: 
23766770.
13. Harichandan A, Bühring HJ. Prospective isolation of human 
MSC. Best Pract Res Clin Haematol. 2011; 24(1): 25–36, doi: 
10.1016/j.beha.2011.01.001, indexed in Pubmed: 21396590.
14. Calabrese G, Giuffrida R, Lo Furno D, et al. Potential effect 
of CD271 on human mesenchymal stromal cell proliferation 
and differentiation. Int J Mol Sci. 2015; 16(7): 15609–15624, 
doi: 10.3390/ijms160715609, indexed in Pubmed: 26184166.
15. Jones E, English A, Churchman SM, et al. Large-scale extrac-
tion and characterization of CD271+ multipotential stromal 
cells from trabecular bone in health and osteoarthritis: impli-
cations for bone regeneration strategies based on uncultured 
or minimally cultured multipotential stromal cells. Arthritis 
Rheum. 2010; 62(7): 1944–1954, doi: 10.1002/art.27451, in-
dexed in Pubmed: 20222109.
16. Tormin A, Li Ou, Brune JC, et al. CD146 expression on pri-
mary nonhematopoietic bone marrow stem cells is correlated 
with in situ localization. Blood. 2011; 117(19): 5067–5077, 
doi: 10.1182/blood-2010-08-304287, indexed in Pubmed: 
21415267.
17. Boxall SA, Jones E. Markers for characterization of bone 
marrow multipotential stromal cells. Stem Cells Int. 2012; 
2012: 975871, doi: 10.1155/2012/975871, indexed in Pubmed: 
22666272.
18. Johnson D, Lanahan A, Buck C, et al. Expression and struc-
ture of the human NGF receptor. Cell. 1986; 47(4): 545–554, 
doi: 10.1016/0092-8674(86)90619-7.
19. Thomson T, Rettig W, Chesa P, et al. Expression of hu-
man nerve growth factor receptor on cells derived from all 
three germ layers. Exp Cell Res. 1988; 174(2): 533–539, doi: 
10.1016/0014-4827(88)90323-0.
20. Hempstead BL. Deciphering proneurotrophin actions. Handb 
Exp Pharmacol. 2014; 220: 17–32, doi: 10.1007/978-3-642-
45106-5_2, indexed in Pubmed: 24668468.
21. Casaccia-Bonnefil P, Gu C, Chao MV. Neurotrophins in 
cell survival/death decisions. Adv Exp Med Biol. 1999; 468: 
275–282, doi: 10.1007/978-1-4615-4685-6_22.
22. Yan H, Schlessinger J, Chao M. Chimeric NGF-EGF re-
ceptors define domains responsible for neuronal differen-
tiation. Science. 1991; 252(5005): 561–563, doi: 10.1126/
science.1850551.
23. Alvarez-Viejo M, Menendez-Menendez Y, Blanco-Gelaz 
AM, et al. LNGFR (CD271) as marker to identify mesenchy-
mal stem cells from different human sources: umbilical cord 
blood, Wharton’s jelly and bone marrow. J Bone Marrow Res. 
2013; 1(4), doi: 10.4172/2329-8820.1000132.
24. Civenni G, Walter A, Kobert N, et al. Human CD271-positive 
melanoma stem cells associated with metastasis establish tu-
mor heterogeneity and long-term growth. Cancer Res. 2011; 
71(8): 3098–3109, doi: 10.1158/0008-5472.CAN-10-3997, in-
dexed in Pubmed: 21393506.
122 Katarzyna Jezierska-Wozniak et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0013
www.fhc.viamedica.pl
25. Imai T, Tamai K, Oizumi S, et al. CD271 defines a stem cell-
like population in hypopharyngeal cancer. PLoS ONE. 2013; 
8(4): e62002, doi: 10.1371/journal.pone.0062002.
26. Murillo-Sauca O, Chung MKi, Shin JHo, et al. CD271 is 
a functional and targetable marker of tumor-initiating cells in 
head and neck squamous cell carcinoma. Oncotarget. 2014; 
5(16): 6854–6866, doi: 10.18632/oncotarget.2269, indexed in 
Pubmed: 25149537.
27. Arufe MC, De la Fuente A, Fuentes I, et al. Chondrogenic 
potential of subpopulations of cells expressing mesenchymal 
stem cell markers derived from human synovial membranes. 
J Cell Biochem. 2010; 111(4): 834–845, doi: 10.1002/jcb.22768, 
indexed in Pubmed: 20665538.
28. Hermida-Gómez T, Fuentes-Boquete I, Gimeno-Longas MJ, 
et al. Bone marrow cells immunomagnetically selected for 
CD271+ antigen promote in vitro the repair of articular carti-
lage defects. Tissue Eng Part A. 2011; 17(7-8): 1169–1179, doi: 
10.1089/ten.TEA.2010.0346, indexed in Pubmed: 21128863.
29. Sakai D, Mochida J, Iwashina T, et al. Regenerative effects 
of transplanting mesenchymal stem cells embedded in atelo-
collagen to the degenerated intervertebral disc. Biomaterials. 
2006; 27(3): 335–345, doi: 10.1016/j.biomaterials.2005.06.038, 
indexed in Pubmed: 16112726.
30. Cai F, Wu XT, Xie XH, et al. Evaluation of intervertebral disc 
regeneration with implantation of bone marrow mesenchymal 
stem cells (BMSCs) using quantitative T2 mapping: a study 
in rabbits. Int Orthop. 2015; 39(1): 149–159, doi: 10.1007/
s00264-014-2481-0, indexed in Pubmed: 25117574.
31. Jeong JeH, Lee JH, Jin ES, et al. Regeneration of interver-
tebral discs in a rat disc degeneration model by implanted 
adipose-tissue-derived stromal cells. Acta Neurochir (Wien). 
2010; 152(10): 1771–1777, doi: 10.1007/s00701-010-0698-2, 
indexed in Pubmed: 20571835.
32. Dominici M, Le Blanc K, Mueller I, et al. Minimal crite-
ria for defining multipotent mesenchymal stromal cells. 
The International Society for Cellular Therapy posi-
tion statement. Cytotherapy. 2006; 8(4): 315–317, doi: 
10.1080/14653240600855905, indexed in Pubmed: 16923606.
33. Yuan M, Leong KW, Chan BP. Three-dimensional culture of 
rabbit nucleus pulposus cells in collagen microspheres. Spine 
J. 2011; 11(10): 947–960, doi: 10.1016/j.spinee.2011.07.004, 
indexed in Pubmed: 21843975.
34. Risbud M, Albert T, Guttapalli A, et al. Differentiation of 
mesenchymal stem cells towards a nucleus pulposus-like phe-
notype in vitro: implications for cell-based transplantation 
therapy. Spine. 2004; 29(23): 2627–2632, doi: 10.1097/01.
brs.0000146462.92171.7f.
35. Barbosa I, Garcia S, Barbier-Chassefière V, et al. Improved 
and simple micro assay for sulfated glycosaminoglycans 
quantification in biological extracts and its use in skin and 
muscle tissue studies. Glycobiology. 2003; 13(9): 647–653, 
doi: 10.1093/glycob/cwg082, indexed in Pubmed: 12773478.
36. Kuçi S, Kuçi Z, Kreyenberg H, et al. CD271 antigen defines 
a subset of multipotent stromal cells with immunosuppressive 
and lymphohematopoietic engraftment-promoting properties. 
Haematologica. 2010; 95(4): 651–659, doi: 10.3324/haema-
tol.2009.015065, indexed in Pubmed: 20179086.
37. Sive JI, Baird P, Jeziorsk M, et al. Expression of chondrocyte 
markers by cells of normal and degenerate intervertebral discs. 
Mol Pathol. 2002; 55(2): 91–97, doi: 10.1136/mp.55.2.91, in-
dexed in Pubmed: 11950957.
38. Kuçi Z, Seiberth J, Latifi-Pupovci H, et al. Clonal analysis of 
multipotent stromal cells derived from CD271+ bone mar-
row mononuclear cells: functional heterogeneity and different 
mechanisms of allosuppression. Haematologica. 2013; 98(10): 
1609–1616, doi: 10.3324/haematol.2013.092700, indexed in 
Pubmed: 23975178.
39. Chan TM, Harn HJ, Lin HP, et al. Improved human mes-
enchymal stem cell isolation. Cell Transplant. 2014; 23(4-5): 
399–406, doi: 10.3727/096368914X678292, indexed in Pub-
med: 24816441.
40. Jarocha D, Lukasiewicz E, Majka M. Adventage of mesenchy-
mal stem cells (MSC) expansion directly from purified bone 
marrow CD105+ and CD271+ cells. Folia Histochem Cyto-
biol. 2008; 46(3): 307–314, doi: 10.2478/v10042-008-0046-z, 
indexed in Pubmed: 19056534.
41. Clouet J, Grimandi G, Pot-Vaucel M, et al. Identification 
of phenotypic discriminating markers for intervertebral disc 
cells and articular chondrocytes. Rheumatology (Oxford). 
2009; 48(11): 1447–1450, doi: 10.1093/rheumatology/kep262, 
indexed in Pubmed: 19748963.
42. Lee CR, Sakai D, Nakai T, et al. A phenotypic comparison 
of intervertebral disc and articular cartilage cells in the rat. 
Eur Spine J. 2007; 16(12): 2174–2185, doi: 10.1007/s00586-
007-0475-y, indexed in Pubmed: 17786487.
43. Minogue BM, Richardson SM, Zeef LAH, et al. Charac-
terization of the human nucleus pulposus cell phenotype 
and evaluation of novel marker gene expression to define 
adult stem cell differentiation. Arthritis Rheum. 2010; 
62(12): 3695–3705, doi: 10.1002/art.27710, indexed in Pub-
med: 20722018.
44. Cui Y, Yu J, Urban JPG, et al. Differential gene expression 
profiling of metalloproteinases and their inhibitors: a com-
parison between bovine intervertebral disc nucleus pulposus 
cells and articular chondrocytes. Spine (Phila Pa 1976). 2010; 
35(11): 1101–1108, doi: 10.1097/BRS.0b013e3181c0c727, in-
dexed in Pubmed: 20473119.
45. Wuertz K, Urban JPG, Klasen J, et al. Influence of extracellu-
lar osmolarity and mechanical stimulation on gene expression 
of intervertebral disc cells. J Orthop Res. 2007; 25(11): 1513–
–1522, doi: 10.1002/jor.20436, indexed in Pubmed: 17568421.
46. Roughley PJ, Geng Y, Mort JS. The non-aggregated aggre-
can in the human intervertebral disc can arise by a non-pro-
teolytic mechanism. Eur Cell Mater. 2014; 12(28): 129–136, 
doi: 10.22203/ecm.v028a10, indexed in Pubmed: 25214019.
47. McDevitt CA. Proteoglycans of the intervertebral disc. In: 
Ghosh P. ed. The biology of the intervertebral disc. Boca 
Raton, FL: CRC Press 1988: 151–170.
48. Henriksson HB, Svanvik T, Jonsson M, et al. Transplantation 
of human mesenchymal stems cells into intervertebral discs 
in a xenogeneic porcine model. Spine (Phila Pa 1976). 2009; 
34(2): 141–148, doi: 10.1097/BRS.0b013e31818f8c20, indexed 
in Pubmed: 19112334.
49. Melrose J, Ghosh P, Taylor T. A comparative analysis of the 
differential spatial and temporal distributions of the large (ag-
grecan, versican) and small (decorin, biglycan, fibromodulin) 
proteoglycans of the intervertebral disc. J Anat. 2001; 198(1): 
3–15, doi: 10.1046/j.1469-7580.2001.19810003.x.
50. Nerlich AG, Schleicher ED, Boos N. 1997 Volvo Award 
winner in basic science studies. Immunohistologic markers 
for age-related changes of human lumbar intervertebral 
discs. Spine (Phila Pa 1976). 1997; 22(24): 2781–2795, doi: 
10.1097/00007632-199712150-00001, indexed in Pubmed: 
9431614.
51. Rutges J, Creemers LB, Dhert W, et al. Variations in gene and 
protein expression in human nucleus pulposus in comparison 
with annulus fibrosus and cartilage cells: potential associations 
with aging and degeneration. Osteoarthritis Cartilage. 2010; 
18(3): 416–423, doi: 10.1016/j.joca.2009.09.009, indexed in 
Pubmed: 19833252.
123CD271 MSCs in IVD regeneration
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0013
www.fhc.viamedica.pl
52. Weiler C, Nerlich AG, Schaaf R, et al. Immunohistochemical 
identification of notochordal markers in cells in the aging human 
lumbar intervertebral disc. Eur Spine J. 2010; 19(10): 1761–1770, 
doi: 10.1007/s00586-010-1392-z, indexed in Pubmed: 20372940.
53. Stoyanov JV, Gantenbein-Ritter B, Bertolo A, et al. Role of 
hypoxia and growth and differentiation factor-5 on differen-
tiation of human mesenchymal stem cells towards interverte-
bral nucleus pulposus-like cells. Eur Cell Mater. 2011; 20(21): 
533–547, doi: 10.22203/ecm.v021a40.
54. Gruber HE, Ingram JA, Hoelscher G, et al. Brain-derived 
neurotrophic factor and its receptor in the human and the 
sand rat intervertebral disc. Arthritis Res Ther. 2008; 10(4): 
R82, doi: 10.1186/ar2456, indexed in Pubmed: 18637190.
55. Purmessur D, Freemont AJ, Hoyland JA. Expression and 
regulation of neurotrophins in the nondegenerate and de-
generate human intervertebral disc. Arthritis Res Ther. 
2008; 10(4): R99, doi: 10.1186/ar2487, indexed in Pubmed: 
18727839.
56. Freemont AJ, Watkins A, Le Maitre C, et al. Nerve growth 
factor expression and innervation of the painful intervertebral 
disc. J Pathol. 2002; 197(3): 286–292, doi: 10.1002/path.1108, 
indexed in Pubmed: 12115873.
Submitted: 19 May, 2017 
Accepted after reviews: 14 August, 2017 
Available as AoP: 18 August, 2017
